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Clinical Indications for 
Therapeutic Cardiac Devices
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Abstract
Both technology and clinical indications have changed since the first cardiac 
devices. Choosing the right therapy, or abstaining from it, is the key to good 
clinical management. Pacemakers effectively reduce symptoms of bradycardia, 
prevent syncope in patients with sick sinus syndrome, and reduce mortality in 
high-degree atrioventricular block. Cardiac resynchronization therapy improves 
symptoms and survival in heart failure patients with reduced ejection fraction 
and ventricular dyssynchrony. Implantable cardioverter defibrillators terminate 
life-threatening ventricular arrhythmias and are indicated for the prevention of 
sudden cardiac death, either as secondary prevention in survivors of ventricular 
fibrillation or ventricular tachycardia with hemodynamic compromise or as 
primary prevention due to heart failure with reduced ejection fraction or other 
miscellaneous diseases. More recently, leadless pacemakers and subcutaneous 
implantable cardioverter defibrillators have been developed as alternatives in 
specific conditions.
Keywords: bradycardia, cardiac devices, cardiac resynchronization therapy,  
heart failure, implantable cardioverter defibrillator, indication, pacemaker,  
sudden cardiac death
1. Introduction
“Those who suffer from frequent and strong faints without any manifest 
cause die suddenly”, Hippocrates stated more than 2000 years ago [1]. This 
is likely a description of arrhythmia-related death, which nowadays often is 
avoidable due to the improvements in diagnostics and treatment the world 
has seen since antiquity.
The majority of patients receiving a pacemaker today are above the age of 
65, owing to increasing problems with impulse generation and conduction with 
age [2]. With the world population getting older, the prevalence of permanent 
pacemakers will likely continue to rise [3]. This chapter aims to present a concise 
description of current guidelines regarding the indications for cardiac devices, 
including pacemakers, cardiac resynchronization therapy (CRT), and implantable 
cardioverter defibrillators (ICD) (Figure 1).
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2. Pacemaker therapy
The medical properties of electricity have been known for some time. The physi-
cians of ancient Rome treated acute gout with electric sea creatures. Alexander von 
Humboldt tested the theory of electrical conduction in biological tissue on himself. 
The first artificial pacemaker, powered by a hand-cranked motor, was invented by 
Albert Hyman in 1932. The first patient to receive an implantable pacemaker, Arne 
Larsson, had to wait until 1958, when he underwent the procedure at the Karolinska 
Figure 1. 
Cardiac devices. From the top: older pacemaker, dual-chamber implantable cardioverter defibrillator, cardiac 
resynchronization therapy-defibrillator, dual-chamber pacemaker, single-chamber pacemaker, and leadless 
pacemaker.
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University Hospital in Stockholm. He outlived both the surgeon Åke Senning and 
the engineer Rune Elmqvist who developed the system [1].
2.1 Etiology
The most common etiology of bradycardia leading to pacemaker implantation is 
conduction tissue fibrosis, but there are several others etiologies responsible for slow 
heart rates according to data from registers, for example the Swedish pacemaker 
registry [4]. Some of these are reversible, such as infection/inflammation, metabolic 
conditions, and medications while others are congenital such as third-degree atrio-
ventricular (AV) block associated with maternal systemic lupus erythematosus [5].
2.2 Pacing mode
A code of four to five letters is used to describe the pacing mode. The first letter 
indicates where pacing occurs (where A stands for atrium, V for ventricle, and D for 
dual); the second describes which chamber is sensed. In the third position, the let-
ters I (inhibit), T (trigger), or D (dual) are used to describe in which way the device 
responds to sensed events. An R in the fourth position means that rate response 
(increased pacing rate during physical exertion) is active. Finally, a fifth letter is 
occasionally used to describe where multicenter pacing is employed (A, V, or D) [6].
2.3 Rate response
The purpose of rate response is to increase the heart rate in response to altered 
demand, and there are different solutions available to achieve this. Activity sensors 
are widely used; one example is the accelerometer that identifies postural changes 
and movement. Minute ventilation sensors can change the heart rate according to 
variations of respiratory rate and tidal volume [7].
2.4 Pacemaker syndrome
The pacemaker syndrome is a condition brought on by the loss of AV synchrony 
caused by ventricular pacing. There are no specific diagnostic criteria, but symptoms 
include orthopnea, dyspnea upon exertion, orthostatic hypotension, and syncope. 
The mode selection trial (MOST), a prospective study of patients with sick sinus 
syndrome (SSS) randomized to VVIR or DDDR pacing, concluded that the incidence 
of pacemaker syndrome was 19.7% at 4 years after implantation. The incidence of 
pacemaker syndrome varies between less than 2 and 83% in multiple studies [8].
2.5 Mode switch
This is crucial in patients with paroxysmal atrial tachyarrhythmias. The cut-off 
for mode-switch is based on sensing of electrical activity of an atrial lead and is 
programmable, typically 180 beats per minute. Atrial flutter activity is sometimes 
hidden in the so-called post-ventricular blanking period and often requires repro-
gramming. Furthermore, nonphysiological electrical activity may lead to oversens-
ing which results in mode-switch.
2.6 Indications for permanent pacing
In bradycardia caused by reversible etiologies, permanent pacing is not war-
ranted, and temporary pacing should instead be considered. Generally, once 
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reversible causes for bradycardia are excluded, the indication for pacing is based on 
the severity of bradycardia rather than its etiology [9]. It should be noted though 
that symptomatic sinus bradycardia as a result of medical therapy is an indication 
for permanent pacing if there are no alternative treatment options [10].
2.6.1 Sinus node dysfunction
Persistent sinus bradycardia, chronotropic incompetence, and sinus arrest 
can all be seen in sinus node disease (SND), a condition that primarily affects the 
elderly [10]. When diagnosing chronotropic incompetence (the inability to increase 
the heart rate as a response to activity or other demands), the fact that heart rate 
is affected by aging, medication, and physical conditioning must be taken into 
account. Exercise testing is the basis for diagnosis [11]. It is important to separate 
physiological bradycardia from inappropriate bradycardia, since sinus bradycardia 
in trained athletes is normal and not an indication for pacemaker therapy [10].
2.6.1.1 Persistent bradycardia
In patients with SND, pacing has not been proven to prolong survival and is 
therefore used to relieve symptoms. Symptoms of bradycardia include impaired 
tolerance to exercise, symptoms of heart failure (HF), syncope, and more subtle 
symptoms like dizziness and forgetfulness. Untreated patients with SSS, however, 
are commonly affected by systemic thromboembolism [9]. A significant reduction 
in stroke and atrial fibrillation (AF) among these patients has been seen with AAI or 
DDD compared with VVI. The DANPACE trial shows that the incidence of paroxys-
mal AF is higher with AAIR pacing than DDDR, and there is a two-fold increase in 
the risk of re-operation [12]. In the Canadian Trial of Physiologic Pacing (CTOPP) 
where physiologic pacing (dual-chamber or atrial) was compared to ventricular pac-
ing in patients with symptomatic bradycardia, a reduction in the risk of AF was seen 
for patients who received dual-chamber pacing. No significant reduction in the risk 
of stroke, death, or hospitalization for HF in the first 3 years after implantation was 
seen with dual-chamber pacing, but the risk of perioperative complications was sig-
nificantly higher in this group [13]. The MOST trial compared ventricular- to dual-
chamber pacing in patients with SSS, and no reduction in stroke with dual-chamber 
pacing was observed. However, a reduction of AF, signs and symptoms of HF, and 
a slight improvement in quality of life was seen [14]. Between 0.6 and 1.9% of all 
patients with SND develop AV block every year, which can of course be a problem 
when AAIR is used [9]. Rate response should be considered (class IIa recommenda-
tion) in people with SND and chronotropic incompetence according to the guide-
lines of the European Society of Cardiology (ESC). The indication is strengthened 
in those who are young and physically active. There is evidence for improvement in 
quality of life and exercise capacity with VVIR compared to VVI. When it comes to 
comparing DDD with DDDR there have been inconsistent results [9]. In extrinsic 
(functional, induced by for example drugs or high vagal tone) bradycardia, the 
prognosis is benign, and pacing is only indicated to prevent recurrent syncope [9].
2.6.1.2 Intermittent bradycardia
Documented symptomatic bradycardia due to sinoatrial block or sinus arrest 
in patients with intrinsic SND (including the brady-tachy form) is a class I recom-
mendation for pacemaker therapy by the ESC [9]. When there is no documented 
correlation between symptoms and electrocardiography (ECG), people with intrin-
sic sinus node dysfunction may still be candidates for cardiac pacing if they have 
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experienced syncope and there are documented asymptomatic ventricular pauses 
of more than 3 seconds. This does not apply to young, well-trained, or medicated 
persons and during sleep. Alternative explanations such as hypotension should be 
ruled out before deciding on pacemaker therapy [9]. The recommendations regard-
ing pacing mode for permanent bradycardia apply for intermittent bradycardia as 
well, based on the fact that there are not enough studies including only patients 
with intermittent bradycardia. Dual-chamber pacing is preferred to reduce the risk 
of pacemaker syndrome [9].
2.6.2 Atrioventricular block
2.6.2.1 Persistent bradycardia
Pacing improves survival in people with AV block (third-degree and second-
degree type 2), as well as prevents recurrence of syncope. There are no randomized 
controlled trials (RCTs), but observational studies from the beginning of the 
pacemaker era suggest this. One study describes a one-year mortality of about 50% 
in patients with complete AV block [15]. Therefore, pacemaker therapy is recom-
mended by the ESC in these patients, even if they are asymptomatic [9]. Permanent 
pacing is controversial in second-degree type 1 AV block; although not if it is symp-
tomatic or the conduction delay is situated at intra- or infra-His levels, in these cases 
pacing should be considered (class of recommendation IIa). If the QRS complex is 
wide, development of complete AV block is more likely [9].
Studies have shown that above one quarter of people with VVI develop pace-
maker syndrome. Dual-chamber pacing reduces the risk of these symptoms. Since 
they require an additional lead and have longer implantation times and a higher risk 
of complications, dual-chamber devices are more expensive. When the risk of AF 
and pacemaker syndrome is taken into account, the cost difference is small over a 
five-year period. Since there is no reduction in morbidity or mortality with dual-
chamber pacing compared to ventricular pacing, the choice should be made on an 
individual basis where increased risk of complications and cost is considered [9]. 
The United Kingdom Pacing and Cardiovascular Events (UKPACE) trial compared 
dual-chamber pacing to ventricular pacing in elderly patients with high grade AV 
block and found that pacing mode does not affect survival, and in contrast with the 
CTOPP trial, no reduction in AF in dual-chamber compared to ventricular pacing 
was seen. Fixed-rate single-chamber pacing was associated with an increased risk 
of stroke, transient ischemic attack, and thromboembolism compared with dual-
chamber pacing, but there was no difference between the rate-adaptive single-
chamber and dual-chamber groups [16].
In permanent AF and AV block, the ESC recommendation (class I recommenda-
tion) is ventricular pacing with rate response [9].
2.6.2.2 Intermittent bradycardia
Correlations between symptoms and ECG are not as important in intrinsic 
third- or second-degree AV block as it is in SSS. The ESC states that cardiac pacing 
is indicated in people suffering from intrinsic intermittent AV block, regardless of 
documentation of correlation between symptoms and ECG findings [9].
2.6.3 Suspected (undocumented) bradycardia
In patients with syncope, the presence of bundle branch block (BBB) suggests that 
the cause may be complete heart block. In spite of this, less than half of patients with 
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BBB and syncope are diagnosed with cardiac syncope. According to the ISSUE 1 study 
and the Bradycardia detection in Bundle Branch Block (B4) study [17] (that included 
patients with normal or preserved systolic function), it is safe to wait until the correct 
diagnosis is made before starting cardiac pacing [9]. ICD or CRT-D should be consid-
ered in patients with syncope who have BBB and HF, previous myocardial infarction, 
or ejection fraction (EF) ≤ 35%. This is because a high incidence of total and sudden 
cardiac death (SCD) has been observed in patients with BBB, and mostly those with 
HF, previous myocardial infarction, or low EF [9]. In patients with BBB who have 
experienced syncope but have normal EF, an electrophysiological study should be 
considered. If this study is abnormal, pacing is a class I recommendation in the ESC 
guidelines [9]. If the electrophysiological study is normal, an insertable cardiac moni-
tor should be considered since EPS cannot rule out intermittent or paroxysmal AV 
block [9].
Cardiac pacing is generally indicated in alternating BBB (block involving all 
three fascicles on successive ECGs) since it is known to progress toward AV block 
fast, even if there is no history of syncope [9]. Asymptomatic BBB is not an indi-
cation for pacemaker therapy. In some cases though, patients with unexplained 
syncope and BBB are candidates for pacemaker therapy, especially old people with 
unpredictable syncope [9].
2.6.4 Carotid sinus syncope
Carotid sinus syncope is defined as a drop in blood pressure of 50 mmHg or 
asystole of more than 3 s as a result of carotid sinus massage [9]. Dual-chamber 
pacing is indicated when asystole of 6 s and syncope follows carotid sinus massage 
(to be performed for a full 10 s, supine and erect), and the patient has recurrent and 
unpredictable syncope [9].
2.6.5 Tilt-induced vasovagal syncope
Tilt-induced vasovagal syncope often affects young people and is in itself a 
benign condition. When deciding whether to implant a pacemaker, this must be 
taken into consideration [9]. Pacing may be considered (class IIb recommendation 
according to ESC) in these patients if they suffer from recurrent and unpredictable 
episodes, are older than 40 years, and have a documented cardio-inhibitory reflex, 
but only after other therapies have failed [9]. As with carotid sinus syncope, dual-
chamber pacing is recommended [9].
2.7 Indications for pacing in specific conditions
2.7.1 Pacing in acute myocardial infarction
Primary angioplasty and thrombolytic therapy have led to a decrease in AV block 
associated with acute myocardial infarction, but it still occurs and when it does, 
mortality is high [10]. When advanced second- or third-degree AV block is seen 
with left bundle branch block (LBBB) or when right bundle branch block occurs 
with left anterior or posterior fascicular block, the prognosis is particularly bad 
[10]. Intraventricular conduction delays develop as a result of extensive damage 
to the myocardium, meaning greater injury to the heart than an isolated electrical 
problem [10]. If the AV block is expected to be temporary, permanent pacemaker 
therapy should be avoided [10]. AV block associated with acute myocardial infarc-
tion resolves spontaneously in 2–7 days in most cases [9]. Permanent AV pacing 
is recommended by the American Heart Association (AHA) in persistent and 
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symptomatic second- or third-degree AV block following acute myocardial infarc-
tion. Persistent second-degree AV block in the His-Purkinje system associated 
with alternating bundle branch block also constitutes an indication for permanent 
ventricular pacing, as well as third-degree AV block within or below the His-
Purkinje system following ST elevation myocardial infarction. In the case of associ-
ated bundle branch block, permanent ventricular pacing is indicated in transient 
advanced second-degree and third-degree infra-nodal AV block according to AHA, 
whereas ESC states that there is no evidence that pacing improves outcomes in these 
patients [9, 10]. Permanent AV pacing may be considered in the case of persistent 
second-degree or third-degree AV block at the AV node level, even if there are no 
symptoms, according to the AHA [10]. According to the ESC, the recommendations 
for pacemaker therapy in permanent AV block following acute myocardial infarc-
tion are the same as those for AV block of other etiologies [9].
2.7.2  Pacing after cardiac surgery, transcatheter aortic valve implantation, and 
heart transplantation
Both AV block and SND may appear as complications after cardiac interven-
tions, and if they persist, permanent pacing must be considered. An observation 
time of up to 7 days is recommended before implanting a permanent pacemaker in 
high degree or complete AV block following cardiac surgery or transcatheter aortic 
valve implantation. A shorter observation time can be used in case of complete AV 
block with a low escape rhythm, where resolution is not likely. SND as a result of 
cardiac surgery or heart transplantation should be observed from 5 days up to some 
weeks before deciding on pacemaker therapy [9].
2.7.3 Pacing in children and in congenital heart disease
When implanting a pacemaker in a young person, several considerations have to 
be made. For one, they will have the pacemaker for a whole lifetime, increasing the 
risk of experiencing complications sometime during this period. They usually have 
higher activity levels than adults, and because of this and the fact that they grow the 
risk of stress on the device and electrode dislodgement is increased. The presence 
of right to left-shunt is a contraindication for endocardial leads; hence, epicardial 
pacing is used instead in this congenital defect. Small body size and the absence 
of transvenous access are other reasons why epicardial pacing is often preferred in 
children. Second-degree type 2 and third-degree AV block are indications (class I 
according to ESC) for pacemaker therapy in children who are symptomatic or if 
any of the following risk factors are present: ventricular dysfunction, prolonged 
QTc interval, complex ventricular ectopy, wide QRS complex escape rhythm, slow 
ventricular rate (<50 beats per minute, ventricular pauses more than three times 
the cycle length of the underlying rhythm) with or without symptoms. For children 
without any risk factors, the ESC states that pacing may be considered in high-
degree and complete AV block, adding that opinions regarding the benefit of pacing 
differ. Pacemaker therapy is indicated for children with SND if they are symptom-
atic and there is a clear correlation between symptoms and bradycardia. The decision 
to implant a pacemaker in a child should be made after discussion with pediatric 
cardiologists, and it is recommended that it is done in a specialized center [9].
2.7.4 Pacing in hypertrophic cardiomyopathy
Patients who have symptoms because of left ventricular outflow tract obstruc-
tion can be treated medically, surgically, with septal alcohol ablation, and 
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sequential AV pacing [9]. Sequential AV pacing is an alternative when myectomy or 
septal alcohol ablation are contraindicated or when the risk of AV block after these 
procedures is considered high [9].
2.7.5 Pacing in pregnancy
Complete heart block with a slow escape rhythm with wide QRS complexes 
should be treated with pacemaker implantation during pregnancy, using echo-
guidance or electro-anatomic navigation to avoid fluoroscopy. The procedure is 
safe, especially when the fetus is beyond 8 weeks of gestation. In case of stable, 
junctional escape rhythm with narrow complexes, pacemaker implantation can be 
delayed until after delivery [9].
2.7.6 Leadless pacemakers
Malfunction of the electrodes is the most common cause of surgical pacemaker 
revision. Pocket hematoma and erosion are other complications associated with 
pacemaker implantation [18]. There are currently two self-contained leadless pace-
maker systems available: Nanostim™ and Micra™. Nanostim™ has been evaluated 
in the prospective nonrandomized study LEADLESS, and the complication-free rate 
compares favorably with traditional pacemaker systems [18]. As for Micra™, the 
risk of major complications in the first 12 months after implantation was 48% lower 
compared to historical control patients with transvenous systems [19]. Currently, 
solely the VVI-mode is available via leadless pacemaker systems. Considering this, 
the higher cost and the fact that there is not much experience outside clinical trials 
with these systems yet, use of leadless pacemakers should for now be reserved for 
when VVI-mode is indicated and transvenous leads are unfeasible or undesirable.
2.8 Emergency temporary pacing
Bradycardia can be a life-threatening condition where immediate action is 
crucial. When the hemodynamics is affected resulting in symptoms of acute HF, 
ischemic chest pain, or signs of shock, the first step is to administer atropine 
intravenously. If atropine is not effective or appropriate, a continuous infusion with 
beta-adrenergic agonists such as isoproterenol, dopamine, or epinephrine is some-
times needed to uphold an adequate pulse until pacemaker therapy can be initiated. 
Another alternative is transcutaneous pacing, which can be used while waiting for 
implantation of a temporary transvenous- or permanent pacemaker [20]. The pads 
are preferably attached with anterior-posterior placement and are then connected 
to the defibrillator/monitor [21]. Transcutaneous pacing can be performed on a 
conscious patient, but sedation is preferred [21, 22]. During transcutaneous pacing, 
the patient must be monitored closely with ECG and with regard to hemodynamic 
stability [9]. Seeing that there are a number of risks associated with temporary 
transvenous pacing (for example, accidental extraction of the pacemaker lead by 
the patient, risk of infection, and thromboembolic events), the ESC recommends 
avoiding this treatment if possible, and otherwise keeping the treatment time as 
brief as possible [9].
3. The implantable cardioverter defibrillator
The first patient to receive an ICD was a woman who had survived repeated 
episodes of ventricular fibrillation (VF) and continued to experience arrhythmias 
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refractory to medical therapy [23]. This was at The Johns Hopkins Hospital in the 
US in 1980, after extensive work by Michel Mirowski and his colleagues. After the 
death of his mentor, who suffered from recurrent ventricular tachyarrhythmias, 
Mirowski’s goal was to create a device that could monitor the heart rhythm and 
administer a defibrillating shock to treat life-threatening tachyarrhythmias [24]. 
Today the ICD is the treatment of choice for both primary and secondary preven-
tion of SCD due to VT/VF [25].
3.1 Etiology
Every year, cardiovascular diseases cause around 17 million deaths worldwide, of 
which SCD makes up approximately 25% [25]. The vast majority of these deaths are 
due to ventricular tachyarrhythmias. According to epidemiological data, 80% of the 
fatal arrhythmias occur as a consequence of structural coronary artery abnormali-
ties. Dilated- and hypertrophic cardiomyopathies are the second most common 
reasons for SCD [26]. Among the young, channelopathies, cardiomyopathies, myo-
carditis, and drug-induced arrhythmias are more common, while coronary artery 
disease, valvular heart diseases, and HF predominate in older individuals [25].
3.2 Cardioversion and antitachycardia pacing
Cardioversion implies that shock delivery is synchronized with the QRS complex 
to avoid inducing VF by delivering a shock during the refractory period of the 
cardiac cycle, and it is recommended for the treatment of several supraventricular 
arrhythmias and monomorphic ventricular tachycardia (VT) with pulses. It should 
not be used to treat VF or pulseless or polymorphic VT, since these arrhythmias 
require unsynchronized high-energy doses, also known as defibrillation [27]. 
Antitachycardia pacing is an alternative way to terminate monomorphic ventricular 
arrhythmias; it can reduce the number of shocks and is generally tolerated well 
since it is rarely noticed by the patient. The mechanism is that a short sequence 
of pacemaker pulses (typically 8–12), with a rate slightly faster than the detected 
tachycardia, is delivered as a response to ventricular arrhythmia. The success rate 
varies but has in some cohorts been shown to exceed 90% [28].
3.3 Indications for ICD
In patients with high risk of SCD, ICD therapy prevents SCD and prolongs life 
(given that life expectancy is not for other reasons less than 1–2 years) [25]. Both 
patients who have experienced previous ventricular arrhythmias and those who are 
at increased risk of future arrhythmia can be protected by ICD therapy.
3.3.1 Secondary prevention
In patients who have survived an episode of documented VF or VT that is not 
hemodynamically tolerated, ICD is a class I recommendation according to the 
ESC, provided that there are no reversible causes and that the expected survival 
with good functional status is at least 1 year [25]. Recurrent sustained VT (not 
including the first 48 hours after myocardial infarction) in patients who are treated 
with optimal medical therapy and have a normal left ventricular EF (LVEF) 
should be considered for ICD therapy (class IIa recommendation). Survival must 
be expected for at least a year with good functional status [25]. Three trials have 
studied the effect of ICD compared to medical treatment as secondary preven-
tion in patients who have survived VF or sustained VT: the antiarrhythmics vs. 
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implantable defibrillator (AVID) study (patients with VT had syncope or serious 
cardiac symptoms and an LVEF of 40% or less) [29], the Cardiac Arrest Study 
Hamburg (CASH) (patients were survivors of cardiac arrest secondary to docu-
mented ventricular arrhythmias) [30], and the Canadian Implantable Defibrillator 
Study (CIDS) (patients with VT had syncope or cardiac symptoms and an LVEF 
of 35% or less; patients with unmonitored syncope and subsequent documenta-
tion of VT were also included) [31]. The AVID study showed an increase in overall 
survival in the ICD group. In the CASH study, the reduction in all-cause mortality 
in the ICD group did not reach statistical significance but there was a 61% reduc-
tion in SCD. The reduction in all-cause mortality and SCD seen in the ICD group 
in the CIDS study was not statistically significant. A meta-analysis of these three 
trials concluded that there is a 28% reduction in total mortality with ICD therapy 
compared to amiodarone, mainly due to a 50% reduction in arrhythmic mortality 
[32]. In the following sections, current guidelines regarding secondary prevention 
in specific circumstances are addressed.
3.3.1.1 Acute coronary syndromes
Approximately 6% of patients with acute coronary syndrome experience VT/VF 
within 48 hours after the first symptoms, the majority during or before reperfusion 
therapy [25, 33]. As stated above, ICD is recommended after an episode of VF or 
hemodynamically compromising VT, unless the episode occurred within 48 hours 
of myocardial infarction, in a patient who receives optimal medical treatment [25].
3.3.1.2 Cardiomyopathies
In patients with hypertrophic cardiomyopathy, dilated cardiomyopathy, left 
ventricular noncompaction cardiomyopathy, and arrhythmogenic right ventricular 
cardiomyopathy, ICD therapy is indicated after a survived episode of cardiac arrest 
due to VT/VF, or in patients who have experienced syncope or hemodynamic com-
promise because of spontaneous sustained VT—in accordance with the guidelines 
in general [25]. When it comes to arrhythmogenic right ventricular cardiomyopa-
thy, the ESC suggests that ICD should be considered (class IIa) in patients who have 
experienced hemodynamically well tolerated sustained VT as well. For patients 
with light-chain amyloidosis or hereditary transthyretin-associated amyloidosis 
who have had a sustained VT with hemodynamic impact, and have a life expectancy 
of more than a year with good functional status, ICD should be considered. This 
recommendation is upgraded to a class I (is recommended) regarding restrictive 
cardiomyopathy [25].
3.3.1.3 Hereditary primary arrhythmia syndromes
ICD therapy and beta-blockers are recommended for patients with long 
QT syndrome and previous cardiac arrest and should be considered in these 
patients if they have experienced syncope or VT while on an adequate dose of 
beta-blockers [25]. In catecholaminergic polymorphic VT, ICD as an addition to 
beta-blockers is recommended after a survived cardiac arrest, recurrent syncope, 
or polymorphic/bidirectional VT during treatment with optimal medical therapy 
[25]. In short QT syndrome and Brugada syndrome, ICD is recommended for 
patients who have survived a cardiac arrest or those who have experienced 
documented spontaneous sustained VT [25]. In Brugada syndrome, an ICD may 
be indicated in primary prevention, especially when syncope is likely due to an 
arrhythmic event [34].
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3.3.2 Primary prevention
3.3.2.1 Heart failure
In the Sudden Cardiac Death in Heart Failure (SCD-HeFT) trial a decrease in the 
overall mortality of 23% was seen in patients with both ischemic and nonischemic 
HF in New York Heart Association (NYHA) functional class II and III and an LVEF 
of 35% or less who received an ICD [35]. An LVEF of 35% or less and symptomatic 
HF (NYHA II-III) after 3 months of optimal medication is a class I indication for 
ICD therapy according to the ESC (provided that the expected survival with good 
functional status is at least 1 year) [25]. More recently, the DANISH trial random-
ized patients with symptomatic HF (LVEF of 35% or less) of nonischemic origin 
to ICD therapy or usual clinical care, and found no overall survival benefit with 
ICD therapy, although the risk of SCD was halved [36]. However, all-cause mortal-
ity was significantly reduced by ICD in patients younger than 59 years old. There 
is currently no indication for ICD therapy in patients with HF in NYHA class IV, 
unless they are listed for heart transplantation since their risk of SCD is generally 
high and the wait is often a year or more [25].
3.3.2.2 Acute coronary syndromes
In 1996, results from the MADIT trial were published, showing that in patients 
with a prior myocardial infarction, NYHA class I-III, LVEF of less than 35%, a 
documented asymptomatic nonsustained VT, and nonsuppressible VT on an 
electrophysiological study, prophylactic ICD therapy leads to improved survival 
[37]. The MADIT-II trial enrolled patients with reduced left ventricular function 
(LVEF 30% or less) after myocardial infarction and found that the patients who 
received ICD therapy had a 31% decrease in all-cause mortality [38]. LVEF should 
be assessed before discharge from the hospital in all patients with acute coronary 
syndrome, and re-assessed 6–12 weeks later, to evaluate whether or not primary 
prevention ICD implantation is indicated. As in nonischemic etiology with LVEF 
of 35% or lower, symptomatic HF (NYHA class II-III), expected survival with 
good functional status for at least 1 year, and optimal medical therapy for at least 
3 months, ICD therapy is recommended (class I recommendation) by the ESC. At 
least 6 weeks must have passed since the myocardial infarction before deciding 
on ICD therapy [25]. The use of an ICD as prophylaxis in patients with a recent 
myocardial infarction (6–40 days previously) does not reduce the overall mortality; 
a reduction in SCD was offset by an increase in nonarrhythmic death [39]. Hence, 
ICD implantation within 40 days of acute myocardial infarction as primary preven-
tion of SCD is generally not indicated but it may be considered in specific cases: 
preexisting impairment in LVEF, incomplete revascularization, and arrhythmia that 
occurs more than 48 hours after acute myocardial infarction [25].
3.3.2.3 Cardiomyopathies
The DEFINITE trial studied patients with nonischemic dilated cardiomyopathy 
with an EF of less than 36% and premature ventricular complexes or nonsustained 
VT, and found that ICD implantation significantly reduced the risk of SCD [40]. 
The same indications for ICD therapy regarding patients with symptomatic heart 
failure apply to patients with dilated cardiomyopathy and left ventricular noncom-
paction cardiomyopathy. In addition to this, ICD should be considered in patients 
with dilated cardiomyopathy who have a verified disease-causing LMNA mutation 
(frequently seen in patients with conduction diseases) and clinical risk factors [25]. 
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Regarding primary prevention in HCM, a calculator that estimates the 5-year risk 
of SCD (HCM Risk-SCD) is recommended by the ESC to evaluate the need for ICD 
therapy in patients aged 16 or older. Based on the risk score, the class of recom-
mendation regarding ICD therapy varies [25]. When it comes to primary prophy-
lactic ICD in patients with arrhythmogenic right ventricular cardiomyopathy, the 
ESC suggests that ICD should be considered in patients who have experienced 
unexplained syncope. ICD may be considered in patients with arrhythmogenic 
right ventricular cardiomyopathy who have at least one risk factor for ventricular 
arrhythmias, including family history of premature SCD and extensive right 
ventricular disease. The risks of ICD therapy should be taken into account when 
considering it as primary prophylactic therapy [25]. Finally, ICD therapy should 
be considered in patients with Chagas disease (a cardiomyopathy caused by the 
parasite Trypanosoma cruzi) who have an EF of less than 40% [25].
3.3.2.4 Hereditary primary arrhythmia syndromes
In patients with long QT syndrome, ICD may be considered (as a comple-
ment to beta-blockers) in patients who are asymptomatic carriers of a pathogenic 
KCNH2- or SCN5A-mutation (high-risk genetic profiles) and have a QTc of more 
than 500 ms [25]. An ICD may be considered as primary prevention in short QT 
syndrome, if there is a family history of SCD and evidence of shortened QT in some 
of these patients. The available data is too scarce for any specific recommendations 
to be made regarding this. As for Brugada syndrome, primary prevention with an 
ICD should be considered in patients with a spontaneous type I ECG pattern and 
suspected arrhythmic syncope in their medical history, and may be considered in 
patients who develop VF during programmed ventricular stimulation [25].
3.3.2.5 Pediatric patients
A number of different etiologies are responsible for the risk of SCD in children: 
channelopathies, cardiomyopathies, and congenital heart disease. The same 
guidelines for when ICD is indicated apply to both adults and children, with the 
exception of dilated cardiomyopathy and advanced dysfunction of the left ven-
tricle since the incidence of SCD is low in this group [25].
3.4 The subcutaneous ICD
This system is placed completely outside the thoracic cavity, eliminating prob-
lems with vascular access and transvenous leads. Subcutaneous ICD therapy is not 
appropriate for patients with bradycardia that requires pacing, for those who have 
indications for CRT or for those who need antitachycardia pacing. When these 
patients are excluded, subcutaneous defibrillators should be considered as an alter-
native to transvenous defibrillators (class IIa recommendation) in patients with an 
ICD indication [25]. According to the ESC, subcutaneous ICD could be considered 
(class IIb recommendation) as an alternative to transvenous defibrillators when 
there are difficulties with venous access, after ICD removal secondary to infection 
or in young patients who will require long-term ICD therapy [25].
3.5 The wearable cardioverter defibrillator
As the name suggests, this defibrillator is entirely external; defibrillator, leads 
and electrode pads are attached to a wearable vest. It may be considered for adult 
patients with reduced LVEF who are waiting for a more permanent solution (cardiac 
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transplantation, transvenous implant) or those who are at a temporary risk of SCD, 
as in peripartum cardiomyopathy or active myocarditis [25, 41].
3.6 Contraindications and considerations
All through the European guidelines concerning ICD indications, it is emphasized 
that the expected survival with good functional status should be at least 1 year for ICD 
to be an option. As mentioned before, symptomatic HF with NYHA class IV is con-
sidered a contraindication, unless the patient is waiting for heart transplantation. VT 
or VF due to reversible causes should not be treated with ICD [25]. Psychiatric illness 
that might be aggravated due to ICD implantation is sometimes considered a contrain-
dication [42], although it is not mentioned as such in the ESC guidelines. Up to a fifth 
of terminally ill patients with an ICD experience shocks in the last weeks of life, and 
deactivation of the ICD should be considered when the patient’s condition worsens. 
This issue should be discussed before implantation and as the illness progresses [25].  
A magnet placed over the ICD will deactivate tachyarrhythmia therapies, and this 
stops inappropriate defibrillations or unnecessary defibrillations at the end of life.
3.7 Health-related quality of life
In its guidelines, the ESC emphasizes the importance of discussing health-
related quality of life issues with the patient before ICD implantation and during 
progression of the disease, by making it a class I recommendation. In addition 
to this, they recommend that patients who experience inappropriate shocks are 
assessed psychologically and treated for any distress [25]. Depression and anxiety 
are common in ICD patients; one systematic review reports anxiety in 8–63% of 
these patients and depression in 5–41% [43]. Similar effects on quality of life have 
been seen in patients with ICD and with medical therapy, with impairment in 
quality of life associated with adverse symptoms in both groups and experience of 
sporadic shocks in the ICD group [44]. Some patients develop post-traumatic stress 
disorder, and these symptoms have been associated with nonconstructive support 
(information that leads to insecurity and fear) from healthcare professionals; 
further studies are needed [45].
4. Cardiac resynchronization therapy
In around 30% of patients suffering from chronic HF, the conduction pathways 
are affected, leading to cardiac dyssynchrony [46]. The aim of CRT is to, as the 
name suggests, improve synchrony in the heart’s contraction [9]. Patients eligible for 
this therapy are those with a wide QRS complex, HF, and impaired left ventricular 
function [47]. Biventricular pacing was first introduced in the early 1990s by Bakker 
et al. and Cazeau et al. [48, 49]. CRT with the ability to work as an ICD is termed 
CRT-D, whereas the term used for a CRT that solely has a pacing function is CRT-P.
4.1 Cardiac dyssynchrony
The dyssynchrony that is targeted with CRT is caused by delays in electrical con-
duction, and the main way to identify this is by assessing the QRS duration (in par-
ticular LBBB) [50]. A prolonged QRS duration has been associated with decreased 
LVEF [51]. In patients with HF, prolongation of the QRS complex has been shown to 
be an independent predictor of increased total mortality and SCD. LBBB is related 
to worse survival but not sudden death [52]. Partially, the mechanism behind 
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dyssynchrony is prolongation of the AV interval, leading to late systolic contraction 
which may take the place of early diastolic filling as well as cause mitral regurgita-
tion. Furthermore, conduction delays between and in the ventricles themselves 
result in asynchronous contraction in the left ventricular walls with subsequent loss 
of cardiac efficiency [9]. Long-standing cardiac dyssynchrony can result in remod-
eling of the heart, causing dilation of the left ventricle, deteriorating diastolic and 
systolic function and worsening of HF [53].
4.2 Important trials
Several trials have been conducted in order to optimize indications for CRT. The 
COmparison of Medical Therapy, Pacing and Defibrillation in Heart Failure 
(COMPANION) trial compared optimal medical therapy, CRT-D, and CRT-P, and 
found that all-cause mortality and hospitalization was reduced in both CRT groups. 
Reduction in mortality was however only marginally significant with CRT-P, but 
significant in the CRT-D group [54]. In the CArdiac REsynchronization in Heart 
Failure (CARE-HF) trial, optimal medical therapy was compared to CRT-P, with the 
result that CRT-P reduced all-cause mortality and hospitalization as well as improved 
symptoms and quality of life [55]. Both of these trials enrolled patients in NYHA class 
III-IV with a QRS duration of 120 ms or more. The Resynchronization-Defibrillation 
for Ambulatory Heart Failure Trial (RAFT) compared the rate of all-cause mortality 
and hospitalization due to HF between patients in NYHA class II or III with a QRS 
duration of at least 120 ms, randomized to either CRT-D or ICD, finding a reduction 
in the primary outcome in the CRT-D group [56].
In the REsynchronization reVErses Remodeling in Systolic left vEntricular dys-
function (REVERSE) trial, patients with HF in NYHA class I and II were randomized 
to CRT (with or without defibrillator) or control. The results showed an improve-
ment in the ventricular structure and function in the CRT group and a decrease in 
hospitalization for HF [57]. MADIT-CRT was designed to evaluate the effect on death 
and HF events in patients in NYHA class I-II who received a CRT-D compared to an 
ICD. The risk of HF events was reduced, left ventricular volumes were reduced, and 
EF improved in the CRT-D group, but no significant difference in all-cause mortality 
was seen between the groups [58]. When the outcomes in MADIT-CRT were studied 
in relationship to whether or not the patient had LBBB, CRT-D led to a reduction in 
HF progression and a reduced risk of ventricular tachyarrhythmias in patients with 
LBBB while patients with non-LBBB morphology did not benefit clinically [59].
4.3 General indications for CRT
4.3.1 Patients in sinus rhythm
CRT is recommended by the ESC (class I recommendation) in patients with 
symptomatic HF in sinus rhythm, with a QRS duration of 130 ms or more, LBBB 
morphology, and an LVEF of 35% or less despite optimal medical therapy, to reduce 
symptoms, morbidity, and mortality [60]. CRT should be considered (class IIa recom-
mendation) in patients who meet these criteria but do not have LBBB morphology 
and have a QRS duration of 150 ms or more and may be considered (class IIb recom-
mendation) in non-LBBB morphology if the QRS duration is between 130 and 149 ms 
[60]. Patients with HF with reduced EF in any NYHA class who have an indication for 
bradycardia pacing with a high proportion of right ventricular pacing (high degree 
AV block, permanent AF) should receive CRT instead of a conventional pacemaker 
in order to reduce morbidity (class I recommendation) [60]. Lastly, patients with HF 
with reduced EF who already have a pacemaker or ICD and develop worsening HF 
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despite optimal medical therapy and have a high rate of ventricular pacing may be 
considered for upgrade to CRT [60].
Since there have been few patients included in RCTs who are in NYHA class I or IV, 
the evidence for CRT in these patients is inconclusive. When it comes to NYHA class 
IV, individual consideration should be made. The recommendations from the ESC 
include patients in NYHA class IV who are ambulatory (no HF hospitalizations in the 
last month) [9].
4.3.2 Patients in atrial fibrillation
Since AF results in irregular and often fast ventricular rates, there is a risk that 
biventricular pacing delivery does not work adequately in these patients, and most 
of the patients with AF and an intact AV node require AV junction ablation in order 
for biventricular pacing to work properly. When considering AV junction ablation 
before CRT implantation, the risk that pacemaker dependency poses must of course 
be taken into account [9]. In its 2013 guidelines, the ESC suggests that CRT should be 
considered in patients with AF who have an EF of 35% or less, are in NYHA class III-IV 
despite optimal medical therapy, and have a QRS duration of at least 120 ms—pro-
vided that bi-ventricular capture of as close to 100% can be achieved. In case bi-ven-
tricular pacing is incomplete, AV junction ablation should be performed [9]. CRT is not 
an indication for AV junction ablation in any other situation than when it is necessary 
because of consistently high ventricular rates despite optimal medical therapy [60]. 
In addition to this, CRT should be considered in patients with reduced EF who are 
candidates for AV junction ablation because of uncontrolled heart rate; a QRS duration 
of more than 120 ms is not necessary [9]. In the slightly more recent guidelines from 
2016 regarding acute and chronic HF, a QRS duration of 130 ms is the cut off for when 
CRT is indicated (applies to patients in sinus rhythm as well as in AF) [60].
4.3.3 Patients with indications for bradycardia pacemakers
Right ventricular pacing might be associated with harmful effects on the cardiac 
function and structure; therefore, upgrading from a conventional pacemaker to CRT 
is recommended in patients with optimal medical therapy who have HF in NYHA 
class III and ambulatory class IV, EF of less than 35%, and a high percentage of right 
ventricular pacing [9]. It should be noted that upgrade to CRT implies a higher risk of 
complications compared to primary implantation [9]. In patients who have indications 
for bradycardia pacing and have not yet received a pacemaker, the ESC guidelines from 
2013 recommend that CRT should be considered if they have a history of HF with 
reduced EF and an expected high rate of ventricular pacing in order to decrease the 
risk of worsening HF [9]. In its 2016 guidelines regarding acute and chronic HF, the 
ESC made CRT a class I recommendation (is recommended) in patients with HF with 
reduced EF regardless of NYHA class, who have an indication for ventricular pacing 
(patients with AF included) [60].
4.3.4 Patients with indications for ICD
Several studies, including the aforementioned RAFT and MADIT-CRT, that have 
compared ICD to CRT-D have found that CRT-D reduces morbidity and mortality. 
Therefore, when a patient is to receive an ICD, the presence of CRT indications (as 
mentioned) should be assessed [9]. According to the ESC guidelines, when ICD 
therapy is indicated in a HF patient who has a QRS complex duration between 130 
and 149 ms, CRT-D should be considered. If the QRS duration is 150 ms or more, 
CRT-D is recommended [60].
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4.3.5 The choice between CRT-P and CRT-D
In order to improve prognosis, evidence points toward the use of CRT-D therapy 
for patients in NYHA class II and CRT-P for patients in NYHA classes III-IV [60]. 
There is not sufficient evidence based on RCTs for the ESC to make a specific 
recommendation on when to choose one over the other, but they offer some advice. 
In addition to patients with advanced HF, the ESC suggests CRT-P in patients with 
severe renal insufficiency and those who have other major comorbidities, cachexia, 
or frailty. CRT-D, on the other hand, is more appropriate in patients with a life expec-
tancy of at least a year, stable HF, no comorbidities, and ischemic heart disease [9].
4.4 Contraindications
According to the Echocardiography Guided Cardiac Resynchronization Therapy 
(EchoCRT) study, there is a risk of increased mortality when CRT is used in 
patients with systolic HF and a QRS duration of less than 130 [61]; QRS of less than 
130 ms is therefore considered a contraindication to CRT by the ESC [60].
4.5 Cardiac contractility modulation
Patients who lack indications for CRT but still suffer from symptomatic HF with 
reduced EF in spite of optimal medical therapy might be candidates for cardiac con-
tractility modulation (CCM). It provides nonexcitatory stimulation of the ventricle 
in its refractory period in order to improve contractility but not cause extra systolic 
contractions [60].
5. Future perspectives
An interesting area of research is the attempt to build biological pacemakers. Stem 
cells and viral vectors have been used to introduce ion-channel genes into the heart 
[62]. These preclinical attempts are promising but much remains until they are ready 
to be considered a clinical option [63]. Nevertheless, electronic devices have been 
developed over decades with proven efficacy, and devastating complications are rare.
Leadless pacing provides a landmark in the development of pacemaker technology. 
However, it is basically limited to pacing from the right ventricle. Because most patients 
will benefit from AV synchronization and even additional cardiac resynchronization, 
efforts are made to fulfill this demand. The AV-sequential challenge could potentially 
be solved by a VDD mode that would rely on atrial sensing from a subcutaneous inte-
grated ECG device. Furthermore, device systems that are able to communicate between 
them are being developed. The subcutaneous ICD could be combined with a leadless 
pacemaker, which could provide sensing/pacing in the right ventricle, including anti-
tachycardia pacing. The ultrasound-based technology WiCS™ system for endocardial 
pacing of the left ventricle is another option that is currently being developed [64]. The 
energy is transmitted from a subcutaneous transmitter subcutaneously to a receiver 
in the endocardium. Leadless pacing in the right ventricular chamber combined with 
the left-ventricular endocardial unit and a subcutaneous pulse generator could be a 
possibility in the near future.
6. Conclusions
Pacemaker therapy has revolutionized the treatment of bradycardia, and with 
an aging population, the use of permanent pacemakers is likely to increase. SCD, 
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